CELLTRION-HEALTHCARE
Celltrion Healthcare has partnered with a leading patient organisation, the European Federation of Crohn’s & Ulcerative Colitis Associations (EFCCA), to raise awareness of inflammatory bowel disease (IBD) this World IBD Day (19 May 2023).
The campaign, Where’s CC? (Crohn’s and Colitis), aims to spark conversations about the impact of IBD across people’s lives and how these challenges vary between different age groups.
People are being encouraged to find the hidden CC characters and learn more about the unique challenges they have faced from being diagnosed with IBD to finding a treatment that works for them, at different stages of life, based on real-life patient insights.
Over ten million people worldwide are living with IBD1, a group of conditions including Crohn’s disease and ulcerative colitis (UC). IBD is most commonly diagnosed between the ages of 10 and 401, however it can appear at any point during people’s lives, with 10% to 15% of newly diagnosed cases of IBD being over the age of 60.2
Clinical research, education and understanding however do not reflect this, leaving groups of people feeling left behind and underrepresented. This can impact patient’s ability to benefit from innovative treatment options and high-quality care, impacting their quality of life and disease outcomes.
Visit www.WhereisCC.com to learn more about the campaign and help in shining a light on IBD by finding CC and learning more about their unique experiences.
Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare, said: “Every IBD patient, no matter their age, deserves to feel understood and have access to high quality care and effective, innovative treatments. Innovations in treatments, including advances in treatment administration that enable people to access at-home injectable treatment allows people to have an improved quality of life whilst managing their condition. We are extremely proud to launch the Where’s CC? campaign in collaboration with EFCCA for World IBD Day 2023 to improve understanding of IBD and the challenges that are associated with specific stages of life.
“Through our partnership with EFCCA, we have unparalleled opportunity to turn the tide in IBD and ensure no patient feels alone or left behind in their unique journey.”
Salvo Leone, EFCCA Chairman, commented: “IBD has no age, yet people living with IBD are facing challenges associated with their age that prevent them benefitting from the best treatment options.
“This World IBD Day, we are delighted to have partnered with Celltrion Healthcare to spotlight some of these challenges to raise awareness and improve care for IBD patients across the world. The Where’s CC? campaign includes important patient resources, and we encourage everyone to spread the word as we work towards a situation where all IBD patients can have a good quality of life.”
Molly O’Donoghue, UC patient, said: “Being diagnosed with UC at 15, I thought I would never be able to move away to university or go travelling with my friends. I was on a downward spiral, becoming depressed and isolated, until I found an at-home treatment that gave me a new freedom to do these things as I had always wanted.
“It is so important that people with IBD are not ashamed of their condition, and we talk about the challenges that come with learning to live with the condition at different stages of life. The Where’s CC? campaign is a brilliant way to raise awareness and help people to overcome the challenges that IBD brings.”
- ENDS -
Notes to Editors:
About Inflammatory Bowel Disease (IBD)
IBD is an umbrella term used to describe conditions including Crohn’s disease and UC. Collectively, IBD impacts over ten million people worldwide.1
IBD is a long-term condition and there may be times when the symptoms are severe, known as a flare-up, and times where there are no or few symptoms, known as remission. Symptoms can be debilitating if the condition is not well managed. These often include abdominal pain and cramping, diarrhoea, weight loss and extreme tiredness.3
Treatment for IBD can be transformative in patients’ lives, reducing the impact of the condition on their lives by minimising flare-up of symptoms and maintaining remission. In recent years, the increasing availability of new treatments has transformed IBD patient care. Innovations in treatments, including advances in treatment administration that enable people to access at-home injectable treatment (versus hospital-based treatment), allows people to have an improved quality of life whilst managing their condition.
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information, please visit: https://www.celltrionhealthcare.com
About EFCCA
The European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) represents 46 national Crohn’s and ulcerative colitis (collectively known as Inflammatory Bowel Disease or IBD) patient associations. We are an organization of people united in our commitment to improve the life of over 10 million people living with IBD worldwide (3.4 million in Europe alone) and to give them a louder voice and more visibility. For more information, please visit: https://efcca.org/
References
1 EFCCA. What is IBD? Available at: https://efcca.org/content/what-ibd [Accessed May 2023]
2 EFCCA. World IBD Day 2023. Available at: https://efcca.org/projects/world-ibd-day-2023 [Accessed May 2023]
3 NHS. Inflammatory bowel disease. Available at: https://www.nhs.uk/conditions/inflammatory-bowel-disease/ [Accessed May 2023]
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005512/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom